INCYCLIX BIO Trademark

Trademark Overview


On Tuesday, March 8, 2022, a trademark application was filed for INCYCLIX BIO with the United States Patent and Trademark Office. The USPTO has given the INCYCLIX BIO trademark a serial number of 97300706. The federal status of this trademark filing is REGISTERED as of Tuesday, October 3, 2023. This trademark is owned by Incyclix Bio, LLC. The INCYCLIX BIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development services in the field of oncology; Research and development of pharmaceuticals and therapeutics in the field oncology; Pharmaceutical product development services in the field of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers; Scientific research for medical purposes in the area of cancerous diseases; Research and development of cyclin-dependent kinase (CDK) based pharmaceuticals for the treatment of cancer and oncological conditions; Research and development in the field of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers; Providing information about medical research in the field of cancerous diseases
incyclix bio

General Information


Serial Number97300706
Word MarkINCYCLIX BIO
Filing DateTuesday, March 8, 2022
Status700 - REGISTERED
Status DateTuesday, October 3, 2023
Registration Number7184421
Registration DateTuesday, October 3, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 24, 2023

Trademark Statements


Disclaimer with Predetermined Text"BIO"
Goods and ServicesPharmaceutical research and development services in the field of oncology; Research and development of pharmaceuticals and therapeutics in the field oncology; Pharmaceutical product development services in the field of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers; Scientific research for medical purposes in the area of cancerous diseases; Research and development of cyclin-dependent kinase (CDK) based pharmaceuticals for the treatment of cancer and oncological conditions; Research and development in the field of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers; Providing information about medical research in the field of cancerous diseases

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, March 12, 2022
Primary Code042
First Use Anywhere DateMonday, February 28, 2022
First Use In Commerce DateMonday, February 28, 2022

Trademark Owner History


Party NameIncyclix Bio, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressResearch Triangle Park, NC 27709

Party NameIncyclix Bio, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressResearch Triangle Park, NC 27709

Party NameIncyclix Bio, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressResearch Triangle Park, NC 27709

Trademark Events


Event DateEvent Description
Tuesday, October 3, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, October 3, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, August 31, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, August 30, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, August 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 9, 2023STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 1, 2023USE AMENDMENT FILED
Wednesday, August 9, 2023SOU EXTENSION 1 GRANTED
Tuesday, August 1, 2023SOU EXTENSION 1 FILED
Wednesday, August 9, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 1, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 1, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, March 21, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 24, 2023PUBLISHED FOR OPPOSITION
Wednesday, January 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 20, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 20, 2022EXAMINER'S AMENDMENT ENTERED
Tuesday, December 20, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 20, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, December 20, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, December 19, 2022ASSIGNED TO EXAMINER
Saturday, March 12, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 11, 2022NEW APPLICATION ENTERED